Etanercept therapy in children with juvenile rheumatoid arthritis.

Etanercept in childhood psoriasis: An experience from Kuwait

The Gulf Journal of Dermatology and Venereology ABSTRACT Psoriasis commonly affects children and adolescents, and the need for safe, effective therapy is a special consideration in the pediatric population. Recently, the use of biologic agents has been extensively studied for the treatment of psoriasis in adults. Of these, etanercept, a tumor necrosis factor-α antagonist, which FDA has approved...

Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis.

Clinical utility of etanercept in the treatment of arthritides in children and adolescents

Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory diseases affecting approximately 300,000 children and adolescents in the United States of unknown cause. It can affect children from the age of 0 years up to the age of 16 years. The International League of Associations of Rheumatology has defined seven subsets of JIA based on several factors including the number of affected...

Macrophage Activation Syndrome and Etanercept in Children with Systemic Juvenile Rheumatoid Arthritis

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?

Recently, the Food and Drug Administration placed a "black box" label on etanercept, and other tumor necrosis factor inhibitors used to treat childhood arthritis, warning of the risk of malignancies. The Food and Drug Administration made their decision based on a review of 48 cases of malignancies identified worldwide in children treated with tumor necrosis factor inhibitors for inflammatory bo...